Agonistes du récepteur du GLP-1 : puissance ou transcendance ? Des outils pour contrôler glycémie et pression artérielle

During the recent international meetings, were reported several trials evaluating the cardiovascular effects of the GLP-1 receptor agonists (GLP1-RA). Here we analyze and criticize the drug-agencies-required methodology used in these studies, which did not lead to equipoise between the arms with regard to risk factors. However, by taking together all these studies, we can conclude that GLP1-RA, when used at their maximal doses, are potent tools in secondary cardiovascular prevention, through leveraging on control of blood glucose and blood pressure.